[1] 孙燕,周际昌.临床肿瘤内科手册[M].4版,北京:人民卫生出版社,2003:106-113.
[2] Cunningham D,Starling N,Rao S,et al.Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom.Capecitabine and oxaliplatin for advanced esophagogastric cancer[J].N Engl J Med,2008,358(1):36-46.
[3] Kang YK,Kang WK,Shin DB,et al.Randomized phase Ⅲ trial of capecitabine/cisplatin(XP) vs continuous infusion of 5-FU/cisplatin(FP) as first-line therapy in patients with advanced gastric cancer:efficacy and safety results[J].J Clin Oncol,2006,24(18S) :LBA4018.
[4] 张红宇,吴昌平,吴骏,等.EOF 与 XELOX 方案治疗晚期胃癌的疗效与不良反应比较[J].蚌埠医学院学报,2012,37(12):1325-1327.
[5] Sakuramoto S,Sasako M,Yamaguchi T,et al.Adjuvant chemotherapy for gastric cancer with S-1,an oral fluoropyrimidine[J].N Engl J Med,2007,357(18):1810-1820.
[6] Koizumi W,Narahara H,Hara T,et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.
[7] Lee JL,Kang YK,Kang HJ,et al.A randomised multicentre phase Ⅱ trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J].Br J Cancer,2008,99(4):584-590.
[8] Seol YM,Song MK,Choi YJ,et al.Oral fluoropyrimidines(capecitabine or S-1) and cisplatin as first-line treatment in elderly patients with advanced gastric cancer:a retrospective study[J].Jpn J Clin Oncol,2009,9(1):43-48.